Form 4: Exact Sciences Executive Brian Baranick Reports Stock Transactions

Brian Baranick, EVP, GM, Precision Oncology at Exact Sciences Corp, reports the vesting of restricted stock units, tax withholding, and acquisition of new restricted stock units.

Summary

• On August 5, 2024, Brian Baranick, EVP, GM, Precision Oncology at Exact Sciences Corp, reported transactions involving Exact Sciences common stock.
• 2,712 restricted stock units vested, resulting in the acquisition of 2,712 shares of common stock.
• 1,375 shares were withheld by Exact Sciences for tax purposes related to the vesting of the restricted stock units at a price of $55.77.
• Baranick also acquired 21,401 new restricted stock units that vest in four equal annual installments beginning August 5, 2025.
• Following these transactions, Baranick directly owns 14,616 shares of common stock and indirectly owns 454 shares held in a 401(k) plan.
• He also holds 65,007 vested and unvested options and restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The granting of new restricted stock units is a slightly positive sign, indicating continued investment in the executive.

Positives

• The granting of 21,401 new restricted stock units to Brian Baranick indicates continued investment in the company's leadership.

Future Outlook

The newly granted restricted stock units vest in four equal annual installments beginning on August 5, 2025, incentivizing continued performance from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors to gauge management's sentiment and confidence in the company's future prospects.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology and healthcare industries to align management's interests with those of shareholders.
• Companies like Illumina, Genomic Health (now part of Exact Sciences), and Myriad Genetics also utilize stock options and restricted stock units as part of their compensation packages.
• The vesting schedules and amounts of equity grants vary depending on the company's size, stage of development, and individual performance.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine executive compensation and tax withholding.
• Employees may view the granting of new restricted stock units as a positive sign of the company's commitment to its leadership.

Key Dates